Article
Santa Barbara, Calif. - Inamed Corporation and its partner Ipsen,a European pharmaceutical company, reported results of a Phase II dosingstudy of their botulinum toxin type A product yesterday at the AAD meeting.
Review Compares Psoriasis Therapies in Asian Populations
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Subgroup Analysis Reveals Equal Benefit of Brodalumab in Obese vs Non-Obese Patients With Psoriasis
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Patients Treated for Acne Exhibit Higher Sebum, Hydration, and TEWL Levels than General Population
Exploring the Atopic Dermatitis Treatment Paradigm and Challenging Cases